Oteracil
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Oteracil
- Molecular weight
- 157.08
- Structure (SMILES)
- O=C(O)c1nc(=O)[nH]c(=O)[nH]1
- 5 azaorotic acid
- 5-azaorotic acid
- allantoxanic acid
- Allantoxanic acid
- gimeracil and oteracil potassium capsule
- oteracil
- Oteracil
- OTERACIL [EMA EPAR]
- oteracil [INN]
- Oteracil [WHO-DD]
- oteracil ema epar
- oteracil inn
- oteracil who dd
- oteracilo
- Oteracilo
- oxonic acid
- Oxonic acid
- OXONIC ACID [MI]
- oxonic acid mi
- s triazine 2 4 dione 6 carboxylic acid
- S-TRIAZINE-2,4-DIONE-6-CARBOXYLIC ACID
- CAS registry numbers
- 937-13-3
- ChEMBL ID
- CHEMBL181932
- InChIKey
- RYYCJUAHISIHTL-UHFFFAOYSA-N
- PubChem compound IDs
- 4604
- FDA ingredient codes (UNII)
- 5VT6420TIG
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -racil
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- UMPS
- Protein identifier
- P11172
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Adenocarcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000228
- Subject identifier
- D000230
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002916
- Subject identifier
- D004938
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003860
- Subject identifier
- D010190
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003897
- Subject identifier
- D013274
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004142
- Subject identifier
- D015179
- Condition
- Cholangiocarcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005221
- Subject identifier
- D018281
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0006859
- Subject identifier
- D006258
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000359
- Subject identifier
- D010190
- Condition
- Rectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000657
- Subject identifier
- D012004
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Carcinoma, Neuroendocrine
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002120
- Subject identifier
- D018278
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002974
- Subject identifier
- D002583
And 10 more, listed on the interactive page.
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000365
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003897
- Condition identifier
- EFO_0004142
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005221
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005922
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006859
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000359
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002120
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Condition identifier
- MONDO_0003060
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005008
- Highest recorded phase
- 3
And 21 more, listed on the interactive page.
- Event
- collateral circulation
- Reports
- 1
- Reporting signal score
- 7.58695
- Event
- decreased appetite
- Reports
- 5
- Reporting signal score
- 11.2788
- Event
- hepatic function abnormal
- Reports
- 3
- Reporting signal score
- 8.87124
- Event
- hepatitis acute
- Reports
- 2
- Reporting signal score
- 8.19425
- Event
- hepatitis b
- Reports
- 2
- Reporting signal score
- 8.55681
- Event
- myositis
- Reports
- 2
- Reporting signal score
- 7.67268
- Event
- portosplenomesenteric venous thrombosis
- Reports
- 1
- Reporting signal score
- 8.28
- Event
- pyogenic granuloma
- Reports
- 2
- Reporting signal score
- 13.2661
- NCT00072787
- NCT00088816
- NCT00134095
- NCT00142350
- NCT00150670
- NCT00152217
- NCT00182611
- NCT00195572
- NCT00202969
- NCT00209638
- NCT00209664
- NCT00209729
- NCT00216034
- NCT00278863
- NCT00287768
- NCT00400179
- NCT00503321
- NCT00687843
- NCT00816543
- NCT00915382
- NCT00960349
- NCT00985556
- NCT01283204
- NCT01285557
- NCT01286766
And 198 more, listed on the interactive page.
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 3
- Polar surface area
- 115.91
- Calculated partition coefficient (ALogP)
- -1.84
- Calculated partition coefficient (XLogP)
- -1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 1
- Heavy atoms
- 11
- Molecular formula
- C4H3N3O4
- Monoisotopic mass
- 157.01235559
- Natural product
- Yes
- Recorded assays
- 7
- Active assays
- 0
Related records
Trials (18)
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
- A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
- A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
- CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer
- Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer
- DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
- Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
- Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
- Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
- Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial
- Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
- Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach
- Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
- SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients
- Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma
In development for (34)
- Adenocarcinoma Phase 3
- Biliary tract cancer Phase 3
- Breast cancer Phase 2
- Breast neoplasm Phase 2
- Cancer Phase 2
- Carcinoma of esophagus Phase 3
- Cervical cancer Phase 1
- Cholangiocarcinoma Phase 3
- Colorectal adenocarcinoma Phase 3
- Colorectal cancer Phase 3
- Colorectal neoplasm Phase 3
- Esophageal cancer Phase 3
- Esophageal squamous cell carcinoma Phase 3
- Exocrine pancreatic carcinoma Phase 3
- Gastric adenocarcinoma Phase 3
- Gastric cancer Phase 3
- Gastric carcinoma Phase 3
- Gastric neoplasm Phase 3
- Gastroesophageal junction adenocarcinoma Phase 3
- Head and neck cancer Phase 3